Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Oncological Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CACNA1G drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen Fragment | CACNA1G Extracellular Loop Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CACNA1G Products |
| Gene Delivery | CACNA1G Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Cell-based assays preserve native 24-TM conformation. |
View CACNA1G Products |
| Benchmark Ab | Anti-CACNA1G Recombinant Antibody Sequence-verified positive control. |
View CACNA1G Products |
| Validator | CACNA1G siRNA Set For knockdown verification in target specificity assays. |
View CACNA1G Products |
| Related Target A | CACNA1H (Cav3.2) Subfamily selectivity screening to eliminate off-target T-type calcium channel activity. |
View CACNA1H Products |
| Related Target B | CACNA1I (Cav3.3) Homolog panel screening to optimize safety profiles in central nervous system drug design. |
View CACNA1I Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-TM Conformation Preservation | Lentivirus Premade Particles enable robust stable cell line generation, avoiding the structural instability of purified 24-TM proteins. |
| Subfamily Selectivity (Cav3.1 vs Cav3.2/3.3) | Sequence-verified homolog panels (CACNA1H, CACNA1I) available for comprehensive counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated siRNA sets included for workflow validation. |
| Assay Artifacts & False Positives | Endotoxin-controlled, high-purity (>95%) fragments with theoretical MW verified by Mass Spectrometry. |
Live CACNA1G R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CACNA1G (Cav3.1) is expanding beyond its traditional boundaries in epilepsy and neuropathic pain into oncology, including glioblastoma and medulloblastoma. As first-generation T-type calcium channel blockers move through clinical evaluation, the next wave of R&D focuses on achieving high subfamily selectivity (Cav3.1 vs. Cav3.2/Cav3.3) and brain-penetrant small molecules. This shift requires highly robust cell-based functional assays to ensure therapeutic index safety and target-specific efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Praxis Precision Medicines, Idorsia | Epilepsy, Essential Tremor, Pain | Calcium Flux & Electrophysiology (Requires stable cell lines constructed via Lentivirus) |
| Antibody / ADC | Academic Institutes, Early Biotech | Oncology (Glioblastoma, Prostate Cancer) | Extracellular epitope binding & internalization (Requires high-purity recombinant loop fragments) |
| RNAi / Gene Therapy | Preclinical Biotech | Genetic Epilepsies, Neurodegenerative Disorders | Knockdown validation (Requires validated siRNA screening sets) |